VAXZEVRIA DIN 02511444
Status: Authorization By Interim Order Revoked
Holder: ASTRAZENECA CANADA INC
Molecule: CHADOX1-S [RECOMBINANT]
Health Canada record
| Active ingredient(s) | CHADOX1-S [RECOMBINANT] 50000000000 VP |
|---|---|
| Dosage form | Solution |
| Route | Intramuscular |
| Schedule | COVID-19 - IO - AUTHORIZATION; SCHEDULE D |
| Class | Human |
| ATC | J07BN02 COVID-19, VIRAL VECTOR, NON-REPLICATING |
| Original market date | |
| Current status date | 19-Nov-2021 |
| Source | Health Canada DPD |
Establishment licence of the holder
AstraZeneca Canada Inc. — licence 100421, currently licensed, last inspection rating C (2023-06-12).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing CHADOX1-S [RECOMBINANT]
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02512947 | COVISHIELD | VERITY PHARMACEUTICALS INC. | Solution | CHADOX1-S [RECOMBINANT] 50000000000 VP | Authorization By Interim Order Expired |
| 02510847 | VAXZEVRIA | ASTRAZENECA CANADA INC | Solution | CHADOX1-S [RECOMBINANT] 50000000000 VP | Cancelled Post Market |